Vandetanib Increases Progression-Free Survival In Patients With Advanced Non Small Cell Lung Cancer - Phase II Study
Results published in the Journal of Clinical Oncology1 show that AstraZeneca’s investigational once-daily oral anti-cancer drug vandetanib in combination with docetaxel, increased progression free survival (PFS) compared with docetaxel alone in a phase II study of 127 patients with pre-treated advanced Non-Small Cell Lung Cancer (NSCLC). The trial, study 6 demonstrated that adding vandetanib 100mg to standard docetaxel therapy improved median PFS to 18.7 weeks (HR=0.
